|Last Price||Today's Change||52-Week Range||Trading Volume|
|3.38||0.06 (+1.81%)||3.02 - 8.41||1.1 million (Below Avg)|
Market data as of 11:35AM 04/17/14. Quotes are delayed by at least 15 min.
Exelixis Receives Approval for COMETRIQ® (Cabozantinib) in the European Union for Treatment of Progressive, Unresectable Locally Advanced or Metastatic Medullary Thyroid Carcinoma
03/25/2014 6:00 AM ET